WHOCC
Postal address:
Norwegian Institute of Public Health
WHO Collaborating Centre for Drug Statistics Methodology
Postboks 222 Sk°yen
0213 Oslo
Norway

Visiting/delivery address:
Myrens verksted 6H
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

List of DDDs for 3 years revision

The DDDs, which will be reviewed at the March 2024 meeting (3 year revision) are listed below.  See also Guidelines: Part III; D Principles for reviewing and changing DDD and Part V; D Requests for changes to DDDs. The deadline for applications for alterations and comments is 1 February 2024.  

 

ATC codeATC level name (INN/generic name)DDDUnitAdm.route
A03FA07itopride0.15gO
A10BJ06semaglutide10.5mgO
A16AB15velmanase alfa10mgP
B02BX08avatrombopag20mgO
B03XA06luspatercept3.33mgP
B06AX01crizanlizumab12.5mgP
C08EX02perhexiline0.2gO
C10AX06omega-3-triglycerides incl. other esters and acids4gO
H02CA03ketoconazole0.6gO
J01MA15gemifloxacin0.2gP
J05AB16remdesivir0.1gP
J05AG05rilpivirine15mgP
J05AH01zanamivir1.2gP
J05AJ04cabotegravir10mgP
J05AJ04cabotegravir30mgO
J05AX29fostemsavir1.2gO
L01EA01imatinib0.4gO
L01EA02dasatinib0.1gO
L01EA03nilotinib0.6gO
L01EA04bosutinib0.4gO
L01EA05ponatinib45mgO
L01EB01gefitinib0.25gO
L01EB02erlotinib0.15gO
L01EB03afatinib40mgO
L01EB04osimertinib80mgO
L01EB07dacomitinib45mgO
L01EC01vemurafenib1.92gO
L01EC02dabrafenib0.3gO
L01EC03encorafenib0.45gO
L01ED01crizotinib 0.5gO
L01ED02ceritinib0.45gO
L01ED03alectinib1.2gO
L01ED04brigatinib0.18gO
L01ED05lorlatinib0.1gO
L01EE01trametinib2mgO
L01EE02cobimetinib45mgO
L01EE03binimetinib90mgO
L01EF01palbociclib94mgO
L01EF02ribociclib0.45gO
L01EF03abemaciclib0.3gO
L01EG01temsirolimus3.57mgP
L01EG02everolimus10mgO
L01EH01lapatinib1.25gO
L01EH02neratinib0.24gO
L01EH03tucatinib0.6gO
L01EJ01ruxolitinib30mgO
L01EJ02fedratinib0.4gO
L01EK01axitinib10mgO
L01EK03tivozanib1mgO
L01EL01ibrutinib0.42gO
L01EL02acalabrutinib0.2gO
L01EL03zanubrutinib0.32gO
L01EM01idelalisib0.3gO
L01EM02copanlisib6.43mgP
L01EM03alpelisib0.3gO
L01EM04duvelisib50mgO
L01EN01erdafitinib9mgO
L01EN02pemigatinib9mgO
L01EX01sunitinib33mgO
L01EX02sorafenib0.8gO
L01EX03pazopanib0.8gO
L01EX04vandetanib0.3gO
L01EX05regorafenib0.12gO
L01EX07cabozantinib60mgO
L01EX08lenvatinib18mgO
L01EX09nintedanib0.38gO
L01EX10midostaurin0.1gO
L01EX12larotrectinib0.2gO
L01EX13gilteritinib0.12gO
L01EX14entrectinib0.6gO
L01EX15pexidartinib0.8gO
L01EX17capmatinib0.8gO
L01EX18avapritinib0.3gO
L01EX19ripretinib0.15gO
L01EX22selpercatinib0.32gO
L01EX23pralsetinib0.4g O
L02BB06darolutamide1.2gO
L04AA38ozanimod0.92mgO
L04AA41imlifidase17.5 1)mgP
L04AA43ravulizumab58.9mgP
L04AA44upadacitinib15mgO
N02BG11mirogabalin25mgO
N03AX24cannabidiol0.7gO
N05AL05amisulpride7.5mgP
N05CF04eszopiclone2mgO
N06AX27esketamine8mgN
N06AX28levomilnacipran40mgO
R03CC15formoterol0.16mgO
V03AG05sodium phosphate8gO
1) course dose

Last updated: 2024-01-26